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Abstract
Escape mutations in HIV-1 cytotoxic T cell (CTL) epitopes can abrogate recognition by the TCR of HIV-1-specific CD8+ T cells,
but may also change interactions with alternative MHC class I receptors. Here, we show that mutational escape in three
HLA-A11-, B8- and B7- restricted immunodominant HIV-1 CTL epitopes consistently enhances binding of the respective
peptide/MHC class I complex to Immunoglobulin-like transcript 4 (ILT4), an inhibitory myelomonocytic MHC class I receptor
expressed on monocytes and dendritic cells. In contrast, mutational escape in an alternative immunodominant HLA-B57-
restricted CTL epitope did not affect ILT4-mediated recognition by myelomonocytic cells. This suggests that in addition to
abrogating recognition by HIV-1-specific CD8 T cells, mutational escape in some, but not all CTL epitopes may mediate
important immunoregulatory effects by increasing binding properties to ILT4, and augmenting ILT4-mediated inhibitory
effects of professional antigen-presenting cells.
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Introduction
Due to its high genetic plasticity, HIV-1 can rapidly form escape
mutations that confer resistance to antiretroviral drugs or abrogate
recognition by adaptive immune responses[1]. This has been
particularly clearly documented in the context of immune pressure
mediated by HIV-1-specific CD8+ T cells, which can induce escape
mutations in targeted epitopes that reduce peptide binding to the
restricting HLA class I allele[2], interfere with recognition by TCR
contact residues[3] or inhibit intracellular epitopic peptide process-
ing[4]. However, in addition to abrogating recognition by HIV-1-
specific CD8+ T cells, escape mutations in cytotoxic T cell (CTL)
epitopes may also affect interactions of CTL epitope/MHC class I
complexes with alternative MHC class I receptors. For instance, a
commonmutation in the immunodominant HLA-B*2705 restricted
gag epitope KK10 (KRWIILGLNK) significantly enhances binding
to ILT4, an inhibitory MHC class I receptor expressed on
monocytes and dendritic cells and causes substantial defects in the
antigen-presenting properties of such cells[5]. By altering interac-
tions between peptide/MHC class I complexes and immunomod-
ulatory MHC class I receptors on myelomonocytic cells, CTL
escape mutations may therefore have important, previously
unrecognized regulatory effects on the functional profile of dendritic
cells and monocytes.
To test whether HIV-1 CTL escape mutations are commonly
associated with altered recognition by myelomonocytic MHC class
I receptors on myelomonocytic cells, we here focused on analyzing
how escape variants in four immunodominant HIV-1 CTL
epitopes change interactions between peptide/MHC class I
complexes and the inhibitory myelomonocytic MHC class I
receptor ILT4. The following epitopes and their variants were
included: The HLA-B*0801 restricted nef epitope FLKEKGGL
(FL8 wt) and its variants FLREKGGL (FL8 K3R) and
FLKEEGGL (FL8 K5E), the HLA-A*1101 restricted gag epitope
ACQGVGGPGHK (AK11 wt) and its frequent variant
ACQGVGGPSHK (AK11 G9S), the HLA-B*0702-restricted
gp120 epitope IPRRIRQGL (IL9 wt) and its common variant
IPTRIRQGL (IL9 R3T) and the HLA-B*5701 restricted gag
epitope TSTLQEQIGW (TW10 wt) and its variant TSTLQE-
QIAW (TW10 G9A). These naturally-occurring variants were all
shown to result from CD8+ T cell mediated immune pressure in
prior studies[2,3,6,7].
Results and Discussion
To analyze how HIV-1 CTL escape mutations alter binding
properties of peptide/MHC class I complexes to MHC class I
receptors expressed on myelomonocytic cells, we initially focused
on the immunodominant B8-FL8 epitope. We observed that a
major naturally occurring escape variant with an amino acid
substitution at position 5 (K5E) in the epitopic peptide
substantially increased binding of the respective tetramer to
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CD14+ monocytes as compared to the tetramer refolded with the
wild type tetramer (Figure 1). An increase in tetramer/pentamer
binding relative to the wild type tetramer/pentamer was also
observed after staining of monocytes with a tetramer incorporating
the K3R variant within the epitopic peptide, however, differences
were less pronounced (Figure 1). We subsequently found that the
two CTL escape variants in the A11-AK11 epitope (G9S) and the
B7-IL9 epitope (R3T) also mediated stronger binding interactions
of the corresponding peptide/MHC class I complexes to
monocytes compared to the respective wild type epitopes. In
contrast, no differences were observed between binding of all of
these tetramers to HLA class I-mismatched T cells; moreover,
CD8 T cells specific for the respective wild type epitopes were not
stained by the corresponding variant tetramers (Figures S1, S2 and
S3), indicating that the specific tetramer/pentamer binding
patterns to monocytes were unrelated to the intrinsic fluorescence
emission characteristics of these reagents. The differential
tetramer/pentamer binding properties to monocytes were signif-
icantly reduced by antibodies that selectively blocked ILT4, while
no effect of ILT4 antibodies on binding interactions between
tetramers and HIV-1-specific CD8 T cells were observed (Figure
S1, S2, S3). This demonstrates that the observed binding of
tetramers to myelomonocytic cells was mediated by the inhibitory
MHC class I receptors ILT4. However, blockade of ILT4 by
antibodies did not fully abrogate binding of the respective
tetramers/pentamers to monocytes, suggesting that interactions
with alternative MHC class I receptors on myelomonocytic cells
might contribute to the recognition of these tetramers/pentamers.
Notably, monocytes express a series of alternative stimulatory and
inhibitory MHC class I receptors that might be involved in
interactions with HLA class I molecules[8]. Moreover, the ILT4-
specific antibody used for this study might have a partial overlap
with ILT2 and we therefore cannot exclude that some of the
tetramer binding was mediated by recognition of ILT2. Yet,
tetramer binding to primary monocytes or dendritic cells has never
been shown to be influenced by ILT2 antibodies in our own [5,9]
and other previous studies [10].
To test if increased recognition of HIV-1 CTL escape variants is
a universal phenomenon, we additionally analyzed how a typical
escape mutation at position 9 in the immunodominant B57-TW10
epitope influences recognition of the corresponding peptide/MHC
class I complex by ILT4 on myelomonocytic cells. These
experiments demonstrated no impact of this escape mutation in
the epitope on interactions with ILT4 on monocytes (Figure 2).
Overall, this suggests that a selected number of mutational escape
mutations increase binding properties of the respective peptide/
MHC class I complexes to ILT4, while other variants do not.
In this study, we show that in three randomly selected HIV-1
CTL epitopes, sequence variations induced by CD8+ T cell
mediated immune pressure can lead to increased binding to the
inhibitory myelomonocytic receptor ILT4 expressed on dendritic
cells and monocytes. As shown in multiple prior studies, 2–3 fold
higher binding of MHC class I complexes to ILT4 translates into a
functional inhibition of the antigen-presenting and cytokine
secretion properties of myelomonocytic cells[5,9]; therefore it is
reasonable to assume that the CTL variants studied here induce
inhibitory functional effects on such professional antigen-present-
ing cells. Overall, these results are in line with the recent
understanding that ILT4 can recognize MHC class I complexes[5]
or CD1d molecules[11] in an antigen-specific fashion. Moreover,
our data suggest that inhibitory, ILT4-mediated immunoregula-
tory effects of CTL epitope escape variants may represent a
relatively common and previously underestimated biological
consequence of HIV-1 sequence diversification. These inhibitory
effects may contribute to the progressive decline of antigen-
presenting properties in myelomonocytic cells during advanced
HIV-1 infection that has been documented in a variety of prior
investigations[12,13]. Thus, our data emphasize that mutational
escape in HIV-1 CTL epitopes may be associated with a complex
pattern of immunoregulatory events that are mediated by altered
recognition of CTL escape variants by myelomonocytic MHC
class I receptors. Recent studies have proposed to include CTL
epitope variants into sequences for HIV-1 vaccine candidates,
which may facilitate the induction of HIV-1-specific CD8+ T cells
with a broader ability to cross-recognize mutated variants[14].
However, inclusion of such variants may be associated with
unwanted ILT4-mediated inhibitory immunoregulatory effects
that decrease the functional properties of myelomonocytic cells
and in this way may contribute to a lower immunogenicity of the
immunogens. Thus, the immunoregulatory effects of CTL escape
variants should be considered when selecting sequences for HIV-1
vaccine candidates.
Methods
To investigate altered recognition of these escape variants by
myelomonocytic MHC class I receptors, we used Phycoerythrin
(PE)-labeled recombinant MHC class I tetramers or pentamers
refolded with the respective wild-type or variant peptides. The B8-
FL8 tetramers were produced at the NIH Tetramer Core Facility;
the A11-AK11 tetramers were purchased from Becton Dickinson
(San Diego, CA) and the B7-IL9 tetramers were obtained from
ProImmune (Oxford, UK). Tetramers/Pentamers refolded with
wild type and corresponding variant peptides were labeled with
identical fluorophores, and were simultaneously synthesized at
their respective production facilities. We tested recognition of these
tetramers to circulating CD14+ monocytes from untreated
chronically HIV-1 infected persons, who had been recruited at
the Massachusetts General Hospital after written informed consent
was obtained according to the Institutional Review Board-
approved study protocol. Briefly, 2 ul of each tetramer/pentamer
was incubated with 16106 freshly isolated PBMC for 20 minutes
at room temperature; after 20 minutes, monoclonal CD14-specific
antibodies were added. Cells were then incubated for additional 10
minutes, washed twice and processed to flow cytometric
acquisition on an LSRII cytometer. To determine whether the
observed binding of tetramers/pentamers to monocytes were
mediated by interactions with the inhibitory myelomonocytic
MHC class I receptor ILT4, experiments were conducted with
Figure 1. Representative flow cytometry dot plot reflecting
binding of HLA-B8-FL8 wild-type and variant tetramers to
CD14+ monocytes.
doi:10.1371/journal.pone.0015084.g001
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Figure 2. HIV-1 CTL escape mutations increase recognition of peptide/MHC class I complexes by the inhibitory myelomonocytic
MHC class I receptor ILT4 on monocytes. Data represent the mean fluorescent intensity of MHC class I tetramers/pentamers refolded with the
indicated epitopic peptide or peptide variant. Tests were performed in the indicated number of individuals. Data show mean and standard deviation.
Significance was tested using paired t-test.
doi:10.1371/journal.pone.0015084.g002
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PBMC that had been pre-incubated with polyclonal ILT4-
blocking antibodies (R&D Systems) for 30 min at 37C prior to
staining with MHC class I tetramers/pentamers.
Supporting Information
Figure S1 Binding of B7-IL9 wild-type tetramer and the
corresponding variant tetramer (IL9 R3T) to HIV-1-
specific CD8 T cells. Dot plots indicate binding of the wild type
and the respective variant tetramer to wild-type-specific CD8 T
cells in the presence or absence of ILT4 blocking antibodies.
(TIF)
Figure S2 Binding of A11-AK11 wild-type tetramer and
the corresponding variant tetramer (AK11 G9S) to HIV-
1-specific CD8 T cells. Dot plots indicate binding of the wild
type and the respective variant tetramer to wild-type-specific CD8
T cells in the presence or absence of ILT4 blocking antibodies.
(TIF)
Figure S3 Binding of B8-FL8 wild-type tetramer and the
corresponding variant tetramers (FL8 K5E and K3R) to
HIV-1-specific CD8 T cells. Dot plots indicate binding of the
wild type and the respective variant tetramer to wild-type-specific
CD8 T cells in the presence or absence of ILT4 blocking
antibodies.
(TIF)
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